Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 13/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | DRD3 | P35462 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14118053 | 1.00 | ADRB2 (0.67) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL4458567 | 1.00 | ADRB2 (0.67) | ADRB2ADRB3ADRB1DRD2PGR | |
| Fumaric Acid SCHEMBL29640688 | 0.85 | ADRB2 (0.64) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL8347843 | 0.83 | ADRB2 (0.69) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL10000683 | 0.83 | ADRB2 (0.69) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL3412030 | 0.83 | ADRB2 (0.66) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL7182431 | 0.81 | ADRB2 (0.56) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL2354898 | 0.81 | ADRB3 (0.53) | ADRB2ADRB3ADRB1DRD2PGR | |
| Formoterol SCHEMBL349579 | 0.81 | ADRB2 (1.00) | ADRB2ADRB3ADRB1DRD2PGR | |
| Arformoterol SCHEMBL6547706 | 0.81 | ADRB2 (1.00) | ADRB2ADRB3ADRB1DRD2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010128355-A3 | IMPROVED PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010128355-A2 | IMPROVED PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2010-11-11 | — | — | WO | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | ADRB2 1776/4885ADRB3 1719/4885ADRB1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.